{"id":745515,"date":"2017-07-25T07:35:00","date_gmt":"2017-07-25T07:35:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/"},"modified":"2025-11-07T01:26:22","modified_gmt":"2025-11-07T06:26:22","slug":"mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/","title":{"rendered":"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4        2017     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of results from the DRIVE-AHEAD study,<br \/>\n      the second of two pivotal Phase 3 clinical trials evaluating the<br \/>\n      efficacy and safety of doravirine, the company\u2019s investigational,<br \/>\n      non-nucleoside reverse transcriptase inhibitor (NNRTI), for the<br \/>\n      treatment of HIV-1 infection. At 48 weeks, the study showed that a<br \/>\n      once-daily single tablet, fixed-dose combination of doravirine (DOR),<br \/>\n      lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) met its<br \/>\n      primary efficacy endpoint of non-inferiority based on the proportion of<br \/>\n      participants achieving levels of HIV-1 RNA less than 50 copies\/mL at 48<br \/>\n      weeks of treatment, compared to a fixed-dose combination of efavirenz<br \/>\n      (EFV), emtricitabine (FTC), and TDF, in treatment-na\u00efve adults infected<br \/>\n      with HIV-1.\n    <\/p>\n<p>\n      In addition, through 48 weeks, statistically significantly fewer<br \/>\n      patients taking DOR\/3TC\/TDF reported pre-specified categories of<br \/>\n      neuropsychiatric events (dizziness, sleep disorders and disturbances,<br \/>\n      and inability to think clearly or concentrate) than patients receiving<br \/>\n      the EFV\/FTC\/TDF regimen. Treatment with DOR\/3TC\/TDF also showed&nbsp;a<br \/>\n      statistically significant lower&nbsp;change from baseline in fasting&nbsp;low<br \/>\n      density lipoprotein cholesterol&nbsp;(LDL-C)&nbsp;and non-high density lipoprotein<br \/>\n      cholesterol (non-HDL-C) compared to EFV\/FTC\/TDF at Week 48. Findings<br \/>\n      from the ongoing DRIVE-AHEAD Phase 3 trial were featured as part of a<br \/>\n      late-breaking oral presentation session at the 9th International<br \/>\n      Conference on HIV Science (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ias2017.org%2F&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=IAS+2017&amp;index=1&amp;md5=ba2c2eeb5702bc6147ad4f70c17aff80\" rel=\"nofollow\">IAS<br \/>\n      2017<\/a>) taking place in Paris, France, from July 23-26, 2017.\n    <\/p>\n<p>\n      \u201cData from DRIVE-AHEAD at 48 weeks show that a fixed-dose combination<br \/>\n      tablet containing doravirine achieved viral suppression in HIV-1<br \/>\n      infected treatment-na\u00efve adults, comparable to a fixed-dose combination<br \/>\n      containing efavirenz,\u201d said Dr. Kathleen Squires, professor and director<br \/>\n      of infectious diseases, Thomas Jefferson University, Philadelphia, PA, a<br \/>\n      study investigator. \u201cThe results for doravirine are encouraging, as it<br \/>\n      may offer appropriate patients a new single-tablet treatment option.\u201d\n    <\/p>\n<p>\n      After 48 weeks of treatment, 84 percent of the 364 treatment-na\u00efve<br \/>\n      patients taking once-daily DOR\/3TC\/TDF achieved levels of HIV-1 RNA &lt;50<br \/>\n      copies\/mL compared to 81 percent of the 364 patients taking once-daily<br \/>\n      EFV\/FTC\/TDF, with an estimated treatment difference of 3.5 percent (95<br \/>\n      percent confidence interval; -2.0, 9.0). Increases in mean CD4+ T-cell<br \/>\n      counts from baseline for the DOR\/3TC\/TDF and EFV\/FTC\/TDF groups were 198<br \/>\n      and 188 cells\/mm<sup>3<\/sup>, respectively, with an estimated treatment<br \/>\n      difference of 10.1 (95 percent confidence interval; -16.1, 36.3). In<br \/>\n      addition, comparable efficacy was observed across both treatment groups<br \/>\n      among individuals with high viral load (HIV-1 RNA &gt;100,000 copies\/mL) at<br \/>\n      baseline, which consisted of 69 patients in the DOR\/3TC\/TDF group and 73<br \/>\n      patients in the EFV\/FTC\/TDF group (Observed Failure approach). Of those<br \/>\n      patients with a high viral load (HIV-1 RNA &gt;100,000 copies\/mL) at<br \/>\n      baseline, 81 percent in the DOR\/3TC\/TDF group and 81 percent in the<br \/>\n      EFV\/FTC\/TDF group achieved the study\u2019s primary endpoint of &lt;50 copies\/mL<br \/>\n      of HIV-1 RNA, with a treatment difference of 1.0 percent (95 percent<br \/>\n      confidence interval; -12.4, 14.3).\n    <\/p>\n<p>\n      The study also met its primary safety endpoint, showing that treatment<br \/>\n      with DOR\/3TC\/TDF resulted in fewer patients reporting events of several<br \/>\n      pre-specified neuropsychiatric adverse events compared to EFV\/FTC\/TDF by<br \/>\n      Week 48, including dizziness (8.8 percent versus 37.1 percent); sleep<br \/>\n      disorders and disturbances (12.1 percent versus 25.5 percent); and<br \/>\n      inability to think clearly or concentrate (4.4 percent versus 8.2<br \/>\n      percent). The 2-sided p-values for treatment differences with respect to<br \/>\n      these three pre-specified categories were p&lt;0.001, p&lt;0.001, and p=0.033,<br \/>\n      respectively.\n    <\/p>\n<p>\n      Furthermore, the reported rates of drug-related adverse events were<br \/>\n      lower in the group taking DOR\/3TC\/TDF (31 percent; 113\/364) versus the<br \/>\n      group taking EFV\/FTC\/TDF (63 percent; 229\/364), representing a -31.9<br \/>\n      percent treatment difference (95 percent confidence\n    <\/p>\n<p>\n      interval, -38.6, -24.8). Treatment discontinuations due to adverse<br \/>\n      events for DOR\/3TC\/TDF and EFV\/FTC\/TDF were 3 percent (11\/364) and 7<br \/>\n      percent (24\/364), respectively.\n    <\/p>\n<p>\n      The most commonly reported adverse events occurring in \u226510 percent of<br \/>\n      patients in the DOR\/3TC\/TDF group compared to the EFV\/FTC\/TDF group<br \/>\n      were: headache (13 percent vs. 12 percent); diarrhea (11 percent vs. 14<br \/>\n      percent); nasopharyngitis (11 percent vs. 9 percent); dizziness (9<br \/>\n      percent vs. 37 percent); nausea (8 percent vs. 11 percent); abnormal<br \/>\n      dreams (5 percent vs. 12 percent) and, rash (5 percent vs. 12 percent),<br \/>\n      respectively.\n    <\/p>\n<p>\n      Treatment-emergent viral mutations leading to any drug-associated<br \/>\n      resistance was detected in 1.6 percent of patients in the group<br \/>\n      receiving DOR\/3TC\/TDF, and 3.3 percent of those in the EFV\/FTC\/TDF<br \/>\n      group, respectively, through Week 48.\n    <\/p>\n<p>\n      An analysis of fasting lipid levels showed a statistically significant<br \/>\n      treatment difference in mean changes from baseline in fasting LDL-C and<br \/>\n      non-HDL-C between the two treatment groups (p&lt;0.0001 for both<br \/>\n      cholesterol types). The mean changes from baseline in levels of fasting<br \/>\n      LDL-C and non-HDL-C among the group taking DOR\/3TC\/TDF was -1.6 mg\/dL<br \/>\n      and -3.8 mg\/dL, respectively; compared to the group taking EFV\/FTC\/TDF<br \/>\n      which was +8.7 mg\/dL and +13.3 mg\/dL, respectively.\n    <\/p>\n<p>\n      \u201cFor more than 30 years, Merck has been at the forefront of HIV research<br \/>\n      and the development of new treatments that make a difference for people<br \/>\n      living with HIV,\u201d said Dr. George Hanna, associate vice president,<br \/>\n      clinical research, Merck Research Laboratories<i>. <\/i>\u201cThe development<br \/>\n      of doravirine is the result of a decade of Merck<i> <\/i>research.<i><br \/>\n      Based on our encouraging Phase 3 study findings, we plan to file<br \/>\n      regulatory applications in Q4 2017.\u201d<\/i>\n    <\/p>\n<p>\n      <b>About DRIVE-AHEAD<\/b>\n    <\/p>\n<p>\n      DRIVE-AHEAD is an ongoing Phase 3 multicenter, double-blind, randomized,<br \/>\n      active comparator-controlled clinical trial evaluating the safety and<br \/>\n      efficacy of a once-daily, single-tablet, fixed-dose combination<br \/>\n      containing doravirine 100 mg, lamivudine 300 mg and tenofovir disoproxil<br \/>\n      fumarate 300 mg versus a once-daily, single-tablet, fixed-dose<br \/>\n      combination containing efavirenz 600 mg, emtricitabine 200 mg, and<br \/>\n      tenofovir disoproxil fumarate 300 mg in treatment-na\u00efve HIV-1 infected<br \/>\n      adults. The primary endpoint of the clinical trial was the proportion of<br \/>\n      participants with levels of HIV-1 RNA &lt;50 copies\/mL at Week 48. The<br \/>\n      primary safety endpoint was the proportion of participants with<br \/>\n      neuropsychiatric adverse events through Week 48 in the following<br \/>\n      pre-specified categories: dizziness, sleep disorders and disturbances,<br \/>\n      and the inability to think clearly or concentrate. The trial consists of<br \/>\n      a 96-week double-blind treatment period (base study) and an open label<br \/>\n      extension after participants complete the base study.\n    <\/p>\n<p>\n      For further information regarding DRIVE-AHEAD please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=065290a4ceb9295bf12ec24299c9648b\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n      clinical trial registry number NCT02403674.\n    <\/p>\n<p>\n      <b>About Doravirine<\/b>\n    <\/p>\n<p>\n      Doravirine (MK1439) is an investigational NNRTI being evaluated by Merck<br \/>\n      for the treatment of HIV-1 infection. Doravirine is being evaluated in<br \/>\n      several ongoing clinical trials as a once-daily fixed dose combination<br \/>\n      with 3TC and TDF or individually for use in combination with other<br \/>\n      antiretroviral agents. Phase 3 trials include DRIVE-AHEAD, a trial<br \/>\n      comparing DOR\/3TC\/TDF to EFV\/FTC\/TDF in treatment-na\u00efve adults;<br \/>\n      DRIVE-FORWARD, a trial comparing DOR to once-daily ritonavir-boosted<br \/>\n      darunavir (DRV+r), each administered in combination with FTC\/TDF or<br \/>\n      abacavir (ABC)\/3TC, in treatment-na\u00efve adults; and DRIVE-SHIFT, a trial<br \/>\n      evaluating a switch to DOR\/3TC\/TDF in HIV-1 infected adults who are<br \/>\n      currently virologically suppressed on another antiretroviral regimen.<br \/>\n      Other ongoing Phase 2 clinical trials include an evaluation of<br \/>\n      DOR\/3TC\/TDF in treatment-na\u00efve adults with transmitted resistance to<br \/>\n      NNRTIs and in individuals switching from efavirenz due to intolerability.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=f40cfc13d1b0dcb83e236863b0b2fbd8\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=dd07e9c36d1866c19a678ee4aa3db52a\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=d6ce9ba17bec7bf43110da689ebbb918\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=5dc7d2909679ae2796c35fde549bf6bc\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=f3e1bdf37981df28247d4bbea9ebe3be\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=79f6b14bbe5b532507f55ab33d91319c\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51594431&amp;newsitemid=20170725005809&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=f0b73117e07e1724a0f5a86de753a5c0\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170725005809r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>Carmen de Gourville,        267-664-0146<br \/>Investor:<br \/>Teri Loxam, 908-740-1986<br \/>Amy Klug,        908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4 2017 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company\u2019s investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of HIV-1 infection. At 48 weeks, the study showed that a once-daily single tablet, fixed-dose combination of doravirine (DOR), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) met its primary efficacy endpoint of non-inferiority based on the proportion of participants achieving levels of HIV-1 RNA less than 50 copies\/mL at 48 weeks of treatment, compared to a fixed-dose combination of efavirenz (EFV), emtricitabine (FTC), and TDF, in treatment-na\u00efve adults infected with HIV-1. In addition, through 48 weeks, statistically significantly fewer patients taking<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745515","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4 2017 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company\u2019s investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of HIV-1 infection. At 48 weeks, the study showed that a once-daily single tablet, fixed-dose combination of doravirine (DOR), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) met its primary efficacy endpoint of non-inferiority based on the proportion of participants achieving levels of HIV-1 RNA less than 50 copies\/mL at 48 weeks of treatment, compared to a fixed-dose combination of efavirenz (EFV), emtricitabine (FTC), and TDF, in treatment-na\u00efve adults infected with HIV-1. In addition, through 48 weeks, statistically significantly fewer patients taking\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\\\/\",\"name\":\"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-07-25T07:35:00+00:00\",\"dateModified\":\"2025-11-07T06:26:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - Merck.com","og_description":"Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4 2017 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company\u2019s investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of HIV-1 infection. At 48 weeks, the study showed that a once-daily single tablet, fixed-dose combination of doravirine (DOR), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) met its primary efficacy endpoint of non-inferiority based on the proportion of participants achieving levels of HIV-1 RNA less than 50 copies\/mL at 48 weeks of treatment, compared to a fixed-dose combination of efavirenz (EFV), emtricitabine (FTC), and TDF, in treatment-na\u00efve adults infected with HIV-1. In addition, through 48 weeks, statistically significantly fewer patients taking","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:22+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/","name":"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-07-25T07:35:00+00:00","dateModified":"2025-11-07T06:26:22+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavirenz-both-in-combination-with-other-antiretroviral-agents-in-pivotal-phase-3-trial-for-t\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9098961f-8d20-4b61-8d20-459692aa5fa6","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-NNRTI-Doravirine-Meets-Primary-Efficacy-Endpoint-of-Non-Inferiority-to-Efavirenz-Both-in-Combination-with-Othe-47E78.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745515\/revisions"}],"predecessor-version":[{"id":3674868,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745515\/revisions\/3674868"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745515"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}